Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease
- Author:
Weiwei ZHAI
1
;
Qiaoling YU
1
;
Ping LIU
1
;
Huizhen WU
1
;
Weiwei ZHAI
2
;
Qiaoling YU
2
;
Ping LIU
2
;
Bo QIU
2
;
Huizhen WU
2
Author Information
- Publication Type:Journal Article
- Keywords: finerenone; mineralocorticoid receptor antagonists; type 2 diabetes mellitus with chronic kidney disease
- From: Chinese Journal of Clinical Pharmacology and Therapeutics 2022;27(9):1067-1074
- CountryChina
- Language:Chinese
- Abstract: Finerenone is a new non-steroidal mineralocorticoid receptor antagonists, which can prevent and treat type 2 diabetes mellitus complicated with chronic kidney disease through antioxidant, anti-inflammatory and anti-fibrosis effects, and has a significant cardiovascular protection effect. Compared with traditional mineralocorticoid receptor antagonists, finerenone has a higher selectivity. In this review, the basic introduction, basic research, clinical research and limitations of finerenone were reviewed in order to provide more ideas and options for the treatment of type 2 diabetes mellitus complicated with chronic kidney disease.
